Monitoring NK cell activity in patients with hematological malignancies

References

• Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937 - 51; http://dx.doi.org/10.1182/blood-2009-03-209262; PMID: 19357394
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. [PMID] Cell 2000; 100:57 - 70; http://dx.doi.org/10.1016/S0092-8674(00)81683-9; PMID: 10647931
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius RE, et al. Innate lymphoid cells--a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13:145 - 9; http://dx.doi.org/10.1038/nri3365; PMID: 23348417
   PubMed Web of Science ®Google Scholar
• Soudja SM, Ruiz AL, Marie JC, Lauvau G. Inflammatory monocytes activate memory CD8(+) T and innate NK lymphocytes independent of cognate antigen during microbial pathogen invasion. Immunity 2012; 37:549 - 62; http://dx.doi.org/10.1016/j.immuni.2012.05.029; PMID: 22940097
   PubMed Web of Science ®Google Scholar
• Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26:503 17; http://dx.doi.org/10.1016/j.immuni.2007.03.006; PMID: 17241958
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503 - 10; http://dx.doi.org/10.1038/ni1582; PMID: 18425107
   PubMed Web of Science ®Google Scholar
• Kastenmüller W, Torabi-Parizi P, Subramanian N, Lämmermann T, Germain RN. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. Cell 2012; 150:1235 - 48; http://dx.doi.org/10.1016/j.cell.2012.07.021; PMID: 22980983
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev 2001; 181:170 - 84; http://dx.doi.org/10.1034/j.1600-065X.2001.1810114.x; PMID: 11513138
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413 - 41; http://dx.doi.org/10.1146/annurev-immunol-032712-095951; PMID: 23298206
   PubMed Web of Science ®Google Scholar
• Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206:1495 - 503; http://dx.doi.org/10.1084/jem.20090681; PMID: 19528259
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. FcγRs in health and disease. Curr Top Microbiol Immunol 2011; 350:105 - 25; http://dx.doi.org/10.1007/82_2010_86; PMID: 20680807
   PubMed Web of Science ®Google Scholar
• Cremer I, Fridman WH, Sautès-Fridman C. Tumor microenvironment in NSCLC suppresses NK cells function. Oncoimmunology 2012; 1:244 - 6; http://dx.doi.org/10.4161/onci.1.2.18309; PMID: 22720258
   PubMed Web of Science ®Google Scholar
• Mamessier E, Bertucci F, Sabatier R, Birnbaum D, Olive D. “Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity. Oncoimmunology 2012; 1:366 - 8; http://dx.doi.org/10.4161/onci.18528; PMID: 22737617
   PubMed Web of Science ®Google Scholar
• Pietra G, Vitale M, Moretta L, Mingari MC. How melanoma cells inactivate NK cells. Oncoimmunology 2012; 1:974 - 5; http://dx.doi.org/10.4161/onci.20405; PMID: 23162776
   PubMed Web of Science ®Google Scholar
• Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25:261 - 7; http://dx.doi.org/10.1016/j.coi.2013.03.004; PMID: 23579076
   PubMed Web of Science ®Google Scholar
• Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944 - 51; http://dx.doi.org/10.1200/JCO.2008.19.6147; PMID: 19858404
   PubMed Web of Science ®Google Scholar
• Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2009; 138:30 - 50; http://dx.doi.org/10.1016/j.cell.2009.06.036; PMID: 19596234
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715 - 27; http://dx.doi.org/10.1038/nri1936; PMID: 16977338
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356:1795 - 9; http://dx.doi.org/10.1016/S0140-6736(00)03231-1; PMID: 11117911
   PubMed Web of Science ®Google Scholar
• Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr., Blaser BW, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009; 114:2667 - 77; http://dx.doi.org/10.1182/blood-2009-02-206532; PMID: 19553639
   PubMed Web of Science ®Google Scholar
• Benson DM Jr., Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012; 120:4324 - 33; http://dx.doi.org/10.1182/blood-2012-06-438028; PMID: 23033266
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754 - 8; http://dx.doi.org/10.1182/blood.V99.3.754; PMID: 11806974
   PubMed Web of Science ®Google Scholar
• Cartron G, Trappe RU, Solal-Céligny P, Hallek M. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 2011; 17:19 - 30; http://dx.doi.org/10.1158/1078-0432.CCR-10-1292; PMID: 21208903
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Neudoerfl C, Mueller BJ, Blume C, Daemen K, Stevanovic-Meyer M, Keil J, Lehner F, Haller H, Falk CS. The Peripheral NK Cell Repertoire after Kidney Transplantation is Modulated by Different Immunosuppressive Drugs. Front Immunol 2013; 4:46; http://dx.doi.org/10.3389/fimmu.2013.00046; PMID: 23450662
   PubMed Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294:15 - 22; http://dx.doi.org/10.1016/j.jim.2004.08.008; PMID: 15604012
   PubMed Web of Science ®Google Scholar
• Bryceson YT, Fauriat C, Nunes JM, Wood SM, Björkström NK, Long EO, Ljunggren HG. Functional analysis of human NK cells by flow cytometry. Methods Mol Biol 2010; 612:335 - 52; http://dx.doi.org/10.1007/978-1-60761-362-6_23; PMID: 20033652
   PubMedGoogle Scholar
• Claus M, Watzl C. Evaluation of human natural killer cell activities in whole blood. Curr. Protoc. Immunol. Ed. John E Coligan Al 2010;Chapter 7:Unit7.39.
   Google Scholar
• Eberlein J, Nguyen TT, Victorino F, Golden-Mason L, Rosen HR, Homann D. Comprehensive assessment of chemokine expression profiles by flow cytometry. J Clin Invest 2010; 120:907 - 23; http://dx.doi.org/10.1172/JCI40645; PMID: 20197626
   PubMed Web of Science ®Google Scholar
• Caligiuri MA. Human natural killer cells. Blood 2008; 112:461 - 9; http://dx.doi.org/10.1182/blood-2007-09-077438; PMID: 18650461
   PubMed Web of Science ®Google Scholar
• Béziat V, Dalgard O, Asselah T, Halfon P, Bedossa P, Boudifa A, Hervier B, Theodorou I, Martinot M, Debré P, et al. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol 2012; 42:447 - 57; http://dx.doi.org/10.1002/eji.201141826; PMID: 22105371
   PubMed Web of Science ®Google Scholar
• Björkström NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, Michaëlsson J, Malmberg KJ, Klingström J, Ahlm C, et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011; 208:13 - 21; http://dx.doi.org/10.1084/jem.20100762; PMID: 21173105
   PubMed Web of Science ®Google Scholar
• Sanchez CJ, Le Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D, Costello RT. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother 2011; 60:1 - 13; http://dx.doi.org/10.1007/s00262-010-0898-x; PMID: 20697893
   PubMed Web of Science ®Google Scholar
• Stojanovic A, Correia MP, Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. . Cancer Microenviron 2013; 6:135 - 46; http://dx.doi.org/10.1007/s12307-012-0125-8; PMID: 23242671
   PubMedGoogle Scholar
• Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B, et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 2010; 116:1299 307; http://dx.doi.org/10.1182/blood-2009-11-253286; PMID: 20651077
   PubMed Web of Science ®Google Scholar
• Björkström NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Björklund AT, Flodström-Tullberg M, Michaëlsson J, Rottenberg ME, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116:3853 - 64; http://dx.doi.org/10.1182/blood-2010-04-281675; PMID: 20696944
   PubMed Web of Science ®Google Scholar
• Björkström NK, Fauriat C, Bryceson YT, Sandberg JK, Ljunggren H-G, Malmberg K-J. Analysis of the KIR repertoire in human NK cells by flow cytometry. Methods Mol Biol 2010; 612:353 - 64; http://dx.doi.org/10.1007/978-1-60761-362-6_24; PMID: 20033653
   PubMedGoogle Scholar
• Ribeiro-dos-Santos P, Turnbull EL, Monteiro M, Legrand A, Conrod K, Baalwa J, Pellegrino P, Shaw GM, Williams I, Borrow P, et al. Chronic HIV infection affects the expression of the 2 transcription factors required for CD8 T-cell differentiation into cytolytic effectors. Blood 2012; 119:4928 - 38; http://dx.doi.org/10.1182/blood-2011-12-395186; PMID: 22490682
   PubMed Web of Science ®Google Scholar
• Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007; 4:e176; http://dx.doi.org/10.1371/journal.pmed.0040176; PMID: 17488182
   PubMed Web of Science ®Google Scholar
• Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, Sautès-Fridman C, Cremer I. Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol 2013; 4:19; http://dx.doi.org/10.3389/fimmu.2013.00019; PMID: 23382731
   PubMed Web of Science ®Google Scholar
• Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol 2012; 2012:196063; http://dx.doi.org/10.1155/2012/196063; PMID: 22567028
   PubMed Web of Science ®Google Scholar
• Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105:251 - 8; http://dx.doi.org/10.1182/blood-2004-04-1422; PMID: 15328155
   PubMed Web of Science ®Google Scholar
• Famularo G, D’Ambrosio A, Quintieri F, Di Giovanni S, Parzanese I, Pizzuto F, Giacomelli R, Pugliese O, Tonietti G. Natural killer cell frequency and function in patients with monoclonal gammopathies. J Clin Lab Immunol 1992; 37:99 - 109; PMID: 1285130
   PubMedGoogle Scholar
• King MA, Radicchi-Mastroianni MA. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. Cytometry 1996; 26:121 - 4; http://dx.doi.org/10.1002/(SICI)1097-0320(19960615)26:2<121::AID-CYTO4>3.0.CO;2-J; PMID: 8817087
   PubMedGoogle Scholar
• Frassanito MA, Silvestris F, Cafforio P, Silvestris N, Dammacco F. IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. Int J Clin Lab Res 1997; 27:48 - 54; http://dx.doi.org/10.1007/BF02827242; PMID: 9144027
   PubMedGoogle Scholar
• Sawanobori M, Suzuki K, Nakagawa Y, Inoue Y, Utsuyama M, Hirokawa K. Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis. Acta Haematol 1997; 98:150 - 4; http://dx.doi.org/10.1159/000203610; PMID: 9352746
   PubMed Web of Science ®Google Scholar
• Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 2006; 20:732 - 3; http://dx.doi.org/10.1038/sj.leu.2404096; PMID: 16437151
   PubMed Web of Science ®Google Scholar
• Jinushi M, Vanneman M, Munshi NC, Tai Y-T, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A 2008; 105:1285 - 90; http://dx.doi.org/10.1073/pnas.0711293105; PMID: 18202175
   PubMed Web of Science ®Google Scholar
• Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 2007; 24:312 7; http://dx.doi.org/10.1007/s12032-007-0007-y; PMID: 17673807
   PubMed Web of Science ®Google Scholar
• von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, Glasmacher A, Märten A, Schmidt-Wolf IG, Brossart P, et al. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immunother 2010; 59:829 - 39; http://dx.doi.org/10.1007/s00262-009-0807-3; PMID: 20024547
   PubMed Web of Science ®Google Scholar
• Pessoa de Magalhães RJ, Vidriales M-B, Paiva B, Fernandez-Gimenez C, García-Sanz R, Mateos M-V, Gutierrez NC, Lecrevisse Q, Blanco JF, Hernández J, et al, Spanish Myeloma Group (GEM), Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 2013; 98:79 - 86; http://dx.doi.org/10.3324/haematol.2012.067272; PMID: 22773604
   PubMed Web of Science ®Google Scholar
• Benson DM Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116:2286 - 94; http://dx.doi.org/10.1182/blood-2010-02-271874; PMID: 20460501
   PubMed Web of Science ®Google Scholar
• Krieg S, Ullrich E. Novel immune modulators used in hematology: impact on NK cells. Front Immunol 2012; 3:388; PMID: 23316191
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210 6; http://dx.doi.org/10.1182/blood.V98.1.210; PMID: 11418454
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005; 128:192 - 203; http://dx.doi.org/10.1111/j.1365-2141.2004.05286.x; PMID: 15638853
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140:36 - 45; PMID: 17995965
   PubMed Web of Science ®Google Scholar
• Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009; 84:553 - 9; http://dx.doi.org/10.1002/ajh.21468; PMID: 19565649
   PubMed Web of Science ®Google Scholar
• Lioznov M, El-Cheikh J, Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010; 45:349 53; http://dx.doi.org/10.1038/bmt.2009.155; PMID: 19483763
   PubMed Web of Science ®Google Scholar
• Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A, et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Exp Hematol 2013; 41:134 - 42, e3; http://dx.doi.org/10.1016/j.exphem.2012.10.004; PMID: 23085463
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10:155 - 67; http://dx.doi.org/10.2174/156800910791054239; PMID: 20088798
   PubMed Web of Science ®Google Scholar
• Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117:1605 - 13; http://dx.doi.org/10.1182/blood-2010-04-278432; PMID: 20978269
   PubMed Web of Science ®Google Scholar